Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Gordon Campbell Like the arms race, the funding of new cancer drugs is an endless upwards spiral. First though, the good news ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...

Drawing on this extensive experience, we are now ready to accelerate the production of antibody-drug ... made of Ultimus ® ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Imagine a world where a cure for sickle cell disease — the blood disorder that afflicts roughly one in every 365 Black Americans — never leaves the lab, because scientists ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

Kremlin says Lebanon pager blasts risk igniting tensions in 'explosive' region Merck, a leading science and technology company, launched the first single-use reactor specifically designed to ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...